Auris Medical AG

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs of inner ear disorders and central nervous system disorders. Auris Medical are focusing on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201). These programs have gone through two Phase 1 trials and will move into proof-of-concept studies in 2019. In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. Sonsuvi® (AM-111) has been granted orphan drug status by the FDA and the EMA and has been granted fast track designation by the FDA.